The Primary Objective is to evaluate the efficacy of GFT505 80mg and GFT505 120mg daily versus placebo in reversing histological steatohepatitis without worsening of fibrosis.
Subjects age 18 to 75 years old who are willing to have liver biopsy (or who just had a biopsy) and meet all study inclusion will be considered. Active study participation will last 52-weeks with a 3 month follow-up period.
Subjects will be reimbursed $50 and a parking pass at each scheduled visit.
For more information, contact Melissa Wagner at 919-684-4798.